Article Text

Download PDFPDF
Weekly Paclitaxel-Carboplatin Regimen in Patients With Primary Advanced or Recurrent Endometrial Carcinoma
  1. Ingrid Vandenput, MD, PhD,,
  2. Ignace Vergote, MD, PhD,,
  3. Patrick Neven, MD, PhD, and
  4. Frédéric Amant, MD, PhD
  1. From Leuven Cancer Institute, Gynecologic Oncology, University Hospitals Leuven, Katholieke Universiteit Leuven, Leuven, Belgium.
  1. Address correspondence and reprint requests to Frédéric Amant, MD, PhD, Division of Gynecological Oncology, Department of Obstetrics and Gynecology, University Hospitals Leuven, Herestraat 49 3000 Leuven, Belgium. E-mail:


Objective The objective of the study was to evaluate the response of weekly paclitaxel/carboplatin in patients with primary advanced or recurrent endometrial cancer.

Methods Eighteen cycles of paclitaxel (60 mg/m2) and carboplatinum (area under the plasma concentration-time curve, 2.7) were administered weekly. Response rates were evaluated according to Response Criteria in Solid Tumors criteria.

Results Paclitaxel/carboplatin weekly was administered to 29 patients. Median age was 62 years (range, 44–80 years). Main histopathologic types were serous/clear cell (n = 16) and endometrioid (n = 9). Patients were divided into a chemonaive group (n = 16) (group 1) and a group with previous chemotherapy (n = 13) (group 2). Response rate for group 1 was as follows: partial remission, n = 8 (50%); stable disease, n = 1 (6%); and progressive disease, n = 7 (44%). Response for group 2: partial remission, n = 5 (39%), and progressive disease, n = 8 (62%). Median progression-free survival and overall survival were 9 months (range, 5–27 months) and 12 months (range, 2–27 months), respectively, for group 1 and 8 months (range, 6–10 months) and 9 months (range, 2–18 months), respectively, for group 2.

Overall 411 weekly treatments were administered. Because of grade 4 bone marrow toxicity, treatments needed to be adjusted as follows: dose reduction of 50% to 75%, n = 81 (20%); dose delay, n = 66 (16%); not administered, n = 6 (1%); and changed to paclitaxel/cisplatin, n = 4 (1%). Twenty-three patients (85%) needed treatment adjustment because of toxicity. Neutropenic fever occurred in 1 patient (4%). The most common nonhematologic toxicities were grade 1 to 2 fatigue (89%) and grade 2 nausea (37%). Seven percent had grade 2 neuropathy. No grade 2 alopecia occurred.

Conclusions Paclitaxel/carboplatin weekly seems effective, however, with a considerable hematologic toxicity. Larger trials are needed to confirm these data.

  • Advanced disease
  • Endometrial cancer
  • Paclitaxel/carboplatin
  • Recurrence
  • Weekly regimen

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Dr Amant is clinical researcher for the Research Foundation, Flanders (F.W.O.).